Visit Contract Pharma
at Stand No. 1G97

Arran Chemical Completes First Phase of “ADAPT” Expansion


Expands selectAZyme enzyme platform to include over 4,000 unique enzymes

Arran Chemical Co., a provider of fine chemicals and pharmaceutical intermediates, has completed the first phase of its ADAPT (Arran Deploys Advanced Production Technologies) expansion with a multi-million investment and application of its selectAZyme technology. 
Acquired by the Almac Group in November 2015, Arran has completed the first phase of a sustained investment program. Manufacturing plant assets have been upgraded with the installation and qualification of a new 6,300 L glass lined and 2m3 Hastelloy vessels, bringing the total manufacturing capacity to approximately 50 m3. This has been accompanied by a major refit of the multi-purpose pilot plant in addition to enhancement of the existing refrigeration, warehousing and waste processing facilities.
With enzyme technology becoming the tool of choice to lower cost of goods and increase process scalability, the company has expanded it selectAZyme enzyme platform to include over 4,000 unique enzymes from diverse biological sources. Many of these pertain to entirely new enzymes classes and are ready for deployment at kilogram to ton scale.
“The deployment of the ADAPT strategy, the recent expansion of core production facilities and the development of next generation manufacturing technologies, sets the pace for future growth.” said Tom Moody, vice president of Technology Development and Commercialization, Arran Chemical Co. “As the demand for outsourced procurement of advanced intermediates and building blocks continues to grow, we remain fixated upon meeting our clients’ present and future requirements for uninterrupted supply.”